Teleflex Medical OEM acquired by MONTAGU PRIVATE EQUITY & Kohlberg

Structured as a definitive carve-out separating Teleflex Medical OEM from its parent corporation Teleflex Incorporated, the transaction transfers the contract development business to private equity sponsors Montagu and Kohlberg & Company. Officially announced on December 9, 2025, the transaction values the target business at an enterprise value of $1–10bn. Under the agreed governance arrangements, the carve-out establishes the acquired operations as an independent, standalone contract development and manufacturing organization (CDMO). Greg Stotts will transition from general manager to Chief Executive Officer of the independent entity upon completion, while Kohlberg operating partner Matt Jennings will assume the position of Chairman of the board of directors. The investment thesis formulated by the acquiring consortium focuses on establishing the business as an autonomous platform, allocating fresh capital toward internal quality management systems, engineering talent, and expanded manufacturing infrastructure to capture demand across minimally invasive therapeutic categories. On the sell side, parent company Teleflex Incorporated divests the division alongside its acute care and interventional urology assets to streamline its corporate footprint toward high-margin proprietary medical segments, committing proceeds to a $1 billion share repurchase authorization. The buyers retained Raymond James as exclusive financial advisor, while Kirkland & Ellis and Ropes & Gray acted as joint legal counsel to structure the cross-border corporate carve-out. Subject to standard closing conditions and regulatory approvals across relevant jurisdictions, formal closing is anticipated in the second half of 2026.